Effectiveness of Ezetimibe in Reducing the Estimated Risk for Fatal Cardiovascular Events in Hypercholesterolaemic Patients with Inadequate Lipid Control While on Statin Monotherapy as Measured by the SCORE Model

Table 2

CHD SCORE at baseline and final (6-week) assessments.

Patient Group	CHD SCORE
	Baseline				6 weeks				Absolute Change				Percent Change
	Mean	SD	95% CI		Mean	SD	95% CI		Mean	SD	95% CI		Mean	SD	95% CI
			Lower	Upper			Lower	Upper			Lower	Upper			Lower	Upper
Hypertension	0.054	0.044	0.050	0.058	0.037	0.030	0.034	0.040	−0.017	0.023	−0.019	−0.015	−0.280	0.243	−0.304	−0.257
Diabetes	0.041	0.034	0.037	0.044	0.029	0.025	0.026	0.032	−0.012	0.017	−0.014	−0.010	−0.264	0.244	−0.290	−0.238
MS*	0.047	0.040	0.043	0.051	0.033	0.028	0.030	0.035	−0.014	0.020	−0.016	−0.012	−0.273	0.250	−0.298	−0.248
Smoking	0.056	0.050	0.049	0.063	0.038	0.034	0.033	0.042	−0.018	0.023	−0.021	−0.014	−0.303	0.211	−0.334	−0.273
Total	0.047	0.040	0.044	0.050	0.034	0.029	0.032	0.036	−0.013	0.020	−0.015	−0.012	−0.254	0.243	−0.271	−0.238

*MS: metabolic syndrome.